Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_1
2
33%
Ph phase_2
3
50%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(2)
Other(2)

Detailed Status

unknown2
Completed2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

unknown233%
completed233%
terminated117%
withdrawn117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib

NCT03008512
unknownphase_2

Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

NCT02739633
completedphase_1

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

NCT00882973
completedphase_3

Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer

NCT00876486
unknownphase_1

Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer

NCT02739529
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03008512Phase 2

A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib

Terminated
NCT02739633Phase 2

Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

Unknown
NCT00882973Phase 1

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Completed
NCT00876486Phase 3

Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer

Completed
NCT02739529Phase 1

Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer

Unknown
NCT01169870Phase 2

Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6